Monday, April 17, 2017

First Xarelto Trial To Begin April 24th

The first bellwether trial in the Xarelto MDL is about to begin and the Plaintiffs have won several import legal motions which will help bolster their claims. Judge Fallon, the Louisiana federal judge overseeing the litigation, denied partial summary judgments from the Defendants on some claims against Bayer AG and Janssen Pharmaceuticals Inc., saying they cannot necessarily blame or use FDA red tape for their lack of label updates or for any noncompliance with Louisiana law. The motions dealt with federal preemption of several of Plaintiffs’ claims.

The first MDL trial is set to begin April 24th, which is one of four set to occur in the coming months. There are more than 16,000 cases pending in the Xarelto MDL, with other cases consolidated in Pennsylvania.

Xarelto (rivaroxaban) is an oral blood thinner medication used to reduce the risk of blood clots and strokes in patients with atrial fibrillation and to treat blood clots in the leg and lungs. However, unlike other blood thinners like Coumadin, Xarelto does not have reversal agents to counteract its anticoagulation effects, according to the FDA.

Plaintiffs who have filed suit have alleged the following injuries:

            Intracranial hemorrhages
            Abdominal hemorrhages
            Retinal hemorrhages
            Epidural hematoma
            Adrenal bleeding
            Excessive blood loss
            GI bleeds
            Death

Pittman, Dutton & Hellums, P.C., is currently investigating and filing Xarelto cases. If you or a loved one were prescribed Xarelto and suffered an irreversible internal bleeding that lead to hospitalization and/or death, contact Booth Samuels at toll free 1-866-515-8880 or by email at booths@pittmanudutton.com.


Thursday, April 13, 2017

Zimmer Biomet Recalls Comprehensive Reverse Shoulder Implants

Zimmer Biomet is recalling 3662 of their Comprehensive Reverse Shoulder implants. These prosthetics are used to treat rotator cuff tears, particularly when conventional surgery has failed. The device aids in helping to restore movement of the shoulder, which is often lost because of the injury. The Zimmer products have a higher fracture rate than the company’s warnings indicate. If the device fractures, revision surgery becomes necessary.

The FDA has labeled this recall as a Class 1 recall, which is the most serious class of recall that can be issued and are classified as urgent. Zimmer Biomet sent notices out December 20, 2016. The FDA did not announce until February 2017 that Zimmer Biomet issued a recall.

The Zimmer shoulders that are recalled were manufactured between August 25, 2008, and September 27, 2011, and distributed between October, 2008, and September, 2015.

Pittman, Dutton & Hellums, P.C., is currently investigating claims against Zimmer Biomet over their Comprehensive Reverse Shoulder implants. If you or a love one was adversely affected by this product, please contact Booth Samuels at booths@pittmandutton.com or call toll free 1-866-515-8880.

Wednesday, April 12, 2017

11th Circuit Affirms Wright Verdict

The 11th US Circuit Court of Appeals upheld a $2.1 million judgment by a jury in the first bellwether trial in a multidistrict litigation involving the Wright Medical Conserve “metal-on-metal” hip replacement device. Wright today faces approximately 585 lawsuits in an MDL over its metal-on-metal hip replacement in Wright Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation.

The jury found that the hip devices were defectively designed and unreasonably dangerous and that it caused the plaintiff’s injuries. They awarded $1.1 million in compensatory damages and $10 million in punitive damages. The punitive damages award was later reduced to $1.1 million by the judge.
In related litigation, Wright settled 1,292 claims in November 2016 in consolidated litigation in Georgia federal court and California state court for $240 million, putting an end to the majority of the pending claims against Wright.
Patients who had revision surgery within eight years of their original Conserve, Lineage or Dynasty hip implant are eligible for the settlement. Conserve Cup devices claims can receive up to $170,000, while those patients implanted with the metal-liner Dynasty and Lineage devices can receive up to $120,000 – per reports.
Wright is also facing 74 lawsuits involving fractures of its Profemur long titanium modular neck hip device. It has been marketed by MicroPort Orthopedics, Inc. of Arlington, TN, since 2013. On June 21, 2016, MicroPort recalled its Conserve Shell, Dynasty® Metal Liner, Procotyl® Metal Liner and Lineage® Metal Liner because of “an increasing overall trend in revisions from 2009 to present, and it was found that there was a specific hazard/harm for “suspected tissue reaction to metal debris.”
If you or a loved one have had hip replacement surgery and have been implanted with a defective hip, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. Our firm is currently investigating claims for those people who have been implanted with hip replacement devices, including Wright, DePuy ASR, and DePuy Pinnacle. If you would like a free case evaluation, please contact Booth Samuels toll free at 1-866-515-8880 or by email at booths@pittmandutton.com.